Kelly Epps-Anderson, MD
Cardiovascular Disease · Fairfax, VANPI 1164569687
Payments from drug & device makers
Across 80 payments — averaging $320.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Shockwave Medical, Inc$20K
- Medtronic$2K
- Abbott$2K
- Boston Scientific$619
- Abiomed$571
- Edwards Lifesciences$353
- plus $498 from 12 others
Across 1 payment — averaging $141.66 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Abiomed$142
What the payments were for
- Travel & lodging$2,30437%
- Food & beverage$3,86863%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Shockwave Medical, Inc | 8 | $19,502 |
| Medtronic | 21 | $2,353 |
| Abbott | 16 | $1,714 |
| Boston Scientific | 9 | $619 |
| Abiomed | 6 | $571 |
| Edwards Lifesciences | 3 | $353 |
| Amgen | 1 | $144 |
| Sanofi | 3 | $76 |
| W. L. Gore & Associates, Inc. | 1 | $65 |
| Novartis | 2 | $46 |
| Seagen Inc. | 2 | $40 |
| E.r. Squibb & Sons, L.L.C. | 2 | $31 |
| Cathworks, Inc. | 1 | $25 |
| Johnson & Johnson | 1 | $16 |
| Livanova USA, Inc. | 1 | $16 |
| Bardy Diagnostics, Inc. | 1 | $14 |
| Chiesi USA, Inc. | 1 | $14 |
| Cardiovascular Systems Inc. | 1 | $10 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$25,609 in reported general payments places this provider in the 85th percentile of 548 cardiovascular disease providers in Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 17 | $27,547 |
| Metoprolol Succinate | 55 | $874 |
| Rosuvastatin Calcium | 53 | $633 |
| Atorvastatin Calcium | 29 | $472 |
| Amlodipine Besylate | 37 | $376 |
| Ezetimibe | 13 | $349 |
| Isosorbide Mononitrate ErIsosorbide Mononitrate | 17 | $180 |
| Losartan Potassium | 16 | $179 |
| ClopidogrelClopidogrel Bisulfate | 13 | $78 |
| Furosemide | 13 | $56 |
Paid to pharmacies, not to this prescriber.
Other cardiovascular disease in Fairfax
- David KopinFairfax$386K
- Jared SpitzFairfax$303K
- Constantine TzirosFairfax$250K
- Eunice YangFairfax$135K
- Tariq HaddadFalls Church$8M
- David LimCharlottesville$6M
- Hamid TaheriManassas$4.9M
- Philip OdonnellWinchester$4.6M
- Antonio AbbateCharlottesville$4M
- George VetrovecRichmond$2.3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.